Business Wire

Kioxia Announces English Version of World’s First AI-Designed Manga

3.6.2020 12:30:00 EEST | Business Wire | Press release

Share

Kioxia Corporation today announced that an English version of “PHAEDO,” a new manga created and designed by AI and human collaboration, inspired by the artistic style of manga legend Osamu Tezuka, will be released on June 3 as part of TEZUKA 2020, the first phase of Kioxia’s #FutureMemories brand campaign. PHAEDO, which debuted in February in Japanese comic magazine “Morning,” will be made available for English-language audiences on Kioxia’s TEZUKA 2020 website. PHAEDO is the world’s first1 international manga created through human collaboration, high-speed and large-capacity memory and advanced AI technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005356/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

"PHAEDO" (Graphic: Business Wire)

The process of developing PHAEDO involved using AI technology to generate the story and create the characters. As a first step, to learn the essence of Tezuka’s work and his characteristics as a writer, AI analyzed 130 manga episodes, written and drawn by Osamu Tezuka, including globally famous titles such as “Astro Boy” and “Black Jack”. Based on this analysis, the AI then generated 129 candidate storylines. As a next step, the AI studied 6000 images and applied transfer learning to generate visuals for the characters.

By analyzing Tezuka’s works, AI was able to generate the physical characteristics of new characters, outlines of new stories, after which illustrators hand-drew clothing and other Tezuka inspired details and writers added dialogue. The project team consisted of engineers from Kioxia, who optimize semiconductor fab productivity and product performance using AI technology, illustrators and writers from Tezuka Productions Co., and AI researchers from Keio University and Future University Hakodate.

PHAEDO is the story of a homeless philosopher and his robot bird, Apollo, who try to solve crimes in Tokyo in 2030. This marks the first time Tezuka’s work has been recreated in 30 years.

Kioxia launched its #FutureMemories campaign last October to commemorate the company’s rebranding as Kioxia. PHAEDO is one of the many ways Kioxia intends to change the world by pursuing the potential of memory to create new value with never-before-seen experiences.

For details about PHAEDO, including videos and interviews, please visit TEZUKA 2020 website.

Notes
1. As of June 3, 2020. Kioxia Corporation research.

About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. The company pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information
Sam Ghirardello (phone: +81-3-5427-7396, SGhirardello@webershandwick.com)
Satoshi Ito (phone: +81-3-5427-7309, SIto@webershandwick.com)
Weber Shandwick (Tokyo)

Natalie Telson (ntelson@webershandwick.com)
Weber Shandwick (New York)

Public Relations
Kota Yamaji (kioxia-hd-pr@kioxia.com )
Kioxia Holdings Corporation

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 06:00:00 EEST | Press release

NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth needed to guide investment, refine product positioning, and identify the features that mattered most in eac

KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release

Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl

IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release

IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye